BNP Paribas Exane analyst Peter Verdult initiated coverage of GSK (GSK) with a Neutral rating and $35.25 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- CDC slides suggest ‘positive surprise’ for GSK, says Goldman Sachs
- GSK CEO says the company can navigate through the tariffs, Bloomberg says
- Trump plans to announce ‘major’ tariff on pharmaceutical imports, Reuters says
- GSK Pharma call volume above normal and directionally bullish
- GSK pushes UK government to give more access to health data, Bloomberg says